Global Radiopharmaceuticals Market by Source (Nuclear Reactors, Cyclotrons), by Application (Neurology, Gastroenterology, Cardiology, Oncology, Nephrology, Neuroendocrinology), by Radioisotop (Gallium-67, Indium-111, Iodine-131, Fluorine-18, Leutetium-177, Iodine-125, Iodine-123, Gallium-68, Yttrium-90, Rubidium-82, Technetium-99) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Up Market Research published a new report titled “Radiopharmaceuticals Market research report which is segmented by Source (Nuclear Reactors, Cyclotrons), by Application (Neurology, Gastroenterology, Cardiology, Oncology, Nephrology, Neuroendocrinology), by Radioisotop (Gallium-67, Indium-111, Iodine-131, Fluorine-18, Leutetium-177, Iodine-125, Iodine-123, Gallium-68, Yttrium-90, Rubidium-82, Technetium-99), By Players/Companies Bayer AG, Advanced Accelerator Application, Mallinckrodt, Major players analyzed include GE Healthcare, Eckert & Ziegler, Jubilant Life Sciences Limited, Philips, IBA Radiopharma Solutions, Siemens Healthineers, antheus Medical Imaging Inc.”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Radiopharmaceuticals Market Research Report |
| By Source | Nuclear Reactors, Cyclotrons |
| By Application | Neurology, Gastroenterology, Cardiology, Oncology, Nephrology, Neuroendocrinology |
| By Radioisotop | Gallium-67, Indium-111, Iodine-131, Fluorine-18, Leutetium-177, Iodine-125, Iodine-123, Gallium-68, Yttrium-90, Rubidium-82, Technetium-99 |
| By Companies | Bayer AG, Advanced Accelerator Application, Mallinckrodt, Major players analyzed include GE Healthcare, Eckert & Ziegler, Jubilant Life Sciences Limited, Philips, IBA Radiopharma Solutions, Siemens Healthineers, antheus Medical Imaging Inc. |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 233 |
| Number of Tables & Figures | 164 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Radiopharmaceuticals Market Report Segments:
The market is segmented by Source (Nuclear Reactors, Cyclotrons), by Application (Neurology, Gastroenterology, Cardiology, Oncology, Nephrology, Neuroendocrinology), by Radioisotop (Gallium-67, Indium-111, Iodine-131, Fluorine-18, Leutetium-177, Iodine-125, Iodine-123, Gallium-68, Yttrium-90, Rubidium-82, Technetium-99).
Radiopharmaceuticals Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Radiopharmaceuticals Market
Overview of the regional outlook of the Radiopharmaceuticals Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Radiopharmaceuticals Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Radiopharmaceuticals Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Nuclear Reactors
2. Cyclotrons
7. By Application:1. Neurology
2. Gastroenterology
3. Cardiology
4. Oncology
5. Nephrology
6. Neuroendocrinology
8. By Radioisotop:1. Gallium-67
2. Indium-111
3. Iodine-131
4. Fluorine-18
5. Leutetium-177
6. Iodine-125
7. Iodine-123
8. Gallium-68
9. Yttrium-90
10. Rubidium-82
11. Technetium-99
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Radiopharmaceuticals Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Radiopharmaceuticals Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Radiopharmaceuticals Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Radiopharmaceuticals Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Radiopharmaceuticals Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Radiopharmaceuticals Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Radiopharmaceuticals Market Size & Forecast, 2018-2028
4.5.1 Radiopharmaceuticals Market Size and Y-o-Y Growth
4.5.2 Radiopharmaceuticals Market Absolute $ Opportunity
Chapter 5 Global Radiopharmaceuticals Market Analysis and Forecast by Source
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Source
5.1.2 Basis Point Share (BPS) Analysis by Source
5.1.3 Absolute $ Opportunity Assessment by Source
5.2 Radiopharmaceuticals Market Size Forecast by Source
5.2.1 Nuclear Reactors
5.2.2 Cyclotrons
5.3 Market Attractiveness Analysis by Source
Chapter 6 Global Radiopharmaceuticals Market Analysis and Forecast by Application
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Application
6.1.2 Basis Point Share (BPS) Analysis by Application
6.1.3 Absolute $ Opportunity Assessment by Application
6.2 Radiopharmaceuticals Market Size Forecast by Application
6.2.1 Neurology
6.2.2 Gastroenterology
6.2.3 Cardiology
6.2.4 Oncology
6.2.5 Nephrology
6.2.6 Neuroendocrinology
6.3 Market Attractiveness Analysis by Application
Chapter 7 Global Radiopharmaceuticals Market Analysis and Forecast by Radioisotop
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Radioisotop
7.1.2 Basis Point Share (BPS) Analysis by Radioisotop
7.1.3 Absolute $ Opportunity Assessment by Radioisotop
7.2 Radiopharmaceuticals Market Size Forecast by Radioisotop
7.2.1 Gallium-67
7.2.2 Indium-111
7.2.3 Iodine-131
7.2.4 Fluorine-18
7.2.5 Leutetium-177
7.2.6 Iodine-125
7.2.7 Iodine-123
7.2.8 Gallium-68
7.2.9 Yttrium-90
7.2.10 Rubidium-82
7.2.11 Technetium-99
7.3 Market Attractiveness Analysis by Radioisotop
Chapter 8 Global Radiopharmaceuticals Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Radiopharmaceuticals Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Radiopharmaceuticals Analysis and Forecast
10.1 Introduction
10.2 North America Radiopharmaceuticals Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Radiopharmaceuticals Market Size Forecast by Source
10.6.1 Nuclear Reactors
10.6.2 Cyclotrons
10.7 Basis Point Share (BPS) Analysis by Source
10.8 Absolute $ Opportunity Assessment by Source
10.9 Market Attractiveness Analysis by Source
10.10 North America Radiopharmaceuticals Market Size Forecast by Application
10.10.1 Neurology
10.10.2 Gastroenterology
10.10.3 Cardiology
10.10.4 Oncology
10.10.5 Nephrology
10.10.6 Neuroendocrinology
10.11 Basis Point Share (BPS) Analysis by Application
10.12 Absolute $ Opportunity Assessment by Application
10.13 Market Attractiveness Analysis by Application
10.14 North America Radiopharmaceuticals Market Size Forecast by Radioisotop
10.14.1 Gallium-67
10.14.2 Indium-111
10.14.3 Iodine-131
10.14.4 Fluorine-18
10.14.5 Leutetium-177
10.14.6 Iodine-125
10.14.7 Iodine-123
10.14.8 Gallium-68
10.14.9 Yttrium-90
10.14.10 Rubidium-82
10.14.11 Technetium-99
10.15 Basis Point Share (BPS) Analysis by Radioisotop
10.16 Absolute $ Opportunity Assessment by Radioisotop
10.17 Market Attractiveness Analysis by Radioisotop
Chapter 11 Europe Radiopharmaceuticals Analysis and Forecast
11.1 Introduction
11.2 Europe Radiopharmaceuticals Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Radiopharmaceuticals Market Size Forecast by Source
11.6.1 Nuclear Reactors
11.6.2 Cyclotrons
11.7 Basis Point Share (BPS) Analysis by Source
11.8 Absolute $ Opportunity Assessment by Source
11.9 Market Attractiveness Analysis by Source
11.10 Europe Radiopharmaceuticals Market Size Forecast by Application
11.10.1 Neurology
11.10.2 Gastroenterology
11.10.3 Cardiology
11.10.4 Oncology
11.10.5 Nephrology
11.10.6 Neuroendocrinology
11.11 Basis Point Share (BPS) Analysis by Application
11.12 Absolute $ Opportunity Assessment by Application
11.13 Market Attractiveness Analysis by Application
11.14 Europe Radiopharmaceuticals Market Size Forecast by Radioisotop
11.14.1 Gallium-67
11.14.2 Indium-111
11.14.3 Iodine-131
11.14.4 Fluorine-18
11.14.5 Leutetium-177
11.14.6 Iodine-125
11.14.7 Iodine-123
11.14.8 Gallium-68
11.14.9 Yttrium-90
11.14.10 Rubidium-82
11.14.11 Technetium-99
11.15 Basis Point Share (BPS) Analysis by Radioisotop
11.16 Absolute $ Opportunity Assessment by Radioisotop
11.17 Market Attractiveness Analysis by Radioisotop
Chapter 12 Asia Pacific Radiopharmaceuticals Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Radiopharmaceuticals Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Radiopharmaceuticals Market Size Forecast by Source
12.6.1 Nuclear Reactors
12.6.2 Cyclotrons
12.7 Basis Point Share (BPS) Analysis by Source
12.8 Absolute $ Opportunity Assessment by Source
12.9 Market Attractiveness Analysis by Source
12.10 Asia Pacific Radiopharmaceuticals Market Size Forecast by Application
12.10.1 Neurology
12.10.2 Gastroenterology
12.10.3 Cardiology
12.10.4 Oncology
12.10.5 Nephrology
12.10.6 Neuroendocrinology
12.11 Basis Point Share (BPS) Analysis by Application
12.12 Absolute $ Opportunity Assessment by Application
12.13 Market Attractiveness Analysis by Application
12.14 Asia Pacific Radiopharmaceuticals Market Size Forecast by Radioisotop
12.14.1 Gallium-67
12.14.2 Indium-111
12.14.3 Iodine-131
12.14.4 Fluorine-18
12.14.5 Leutetium-177
12.14.6 Iodine-125
12.14.7 Iodine-123
12.14.8 Gallium-68
12.14.9 Yttrium-90
12.14.10 Rubidium-82
12.14.11 Technetium-99
12.15 Basis Point Share (BPS) Analysis by Radioisotop
12.16 Absolute $ Opportunity Assessment by Radioisotop
12.17 Market Attractiveness Analysis by Radioisotop
Chapter 13 Latin America Radiopharmaceuticals Analysis and Forecast
13.1 Introduction
13.2 Latin America Radiopharmaceuticals Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Radiopharmaceuticals Market Size Forecast by Source
13.6.1 Nuclear Reactors
13.6.2 Cyclotrons
13.7 Basis Point Share (BPS) Analysis by Source
13.8 Absolute $ Opportunity Assessment by Source
13.9 Market Attractiveness Analysis by Source
13.10 Latin America Radiopharmaceuticals Market Size Forecast by Application
13.10.1 Neurology
13.10.2 Gastroenterology
13.10.3 Cardiology
13.10.4 Oncology
13.10.5 Nephrology
13.10.6 Neuroendocrinology
13.11 Basis Point Share (BPS) Analysis by Application
13.12 Absolute $ Opportunity Assessment by Application
13.13 Market Attractiveness Analysis by Application
13.14 Latin America Radiopharmaceuticals Market Size Forecast by Radioisotop
13.14.1 Gallium-67
13.14.2 Indium-111
13.14.3 Iodine-131
13.14.4 Fluorine-18
13.14.5 Leutetium-177
13.14.6 Iodine-125
13.14.7 Iodine-123
13.14.8 Gallium-68
13.14.9 Yttrium-90
13.14.10 Rubidium-82
13.14.11 Technetium-99
13.15 Basis Point Share (BPS) Analysis by Radioisotop
13.16 Absolute $ Opportunity Assessment by Radioisotop
13.17 Market Attractiveness Analysis by Radioisotop
Chapter 14 Middle East & Africa (MEA) Radiopharmaceuticals Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Radiopharmaceuticals Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Radiopharmaceuticals Market Size Forecast by Source
14.6.1 Nuclear Reactors
14.6.2 Cyclotrons
14.7 Basis Point Share (BPS) Analysis by Source
14.8 Absolute $ Opportunity Assessment by Source
14.9 Market Attractiveness Analysis by Source
14.10 Middle East & Africa (MEA) Radiopharmaceuticals Market Size Forecast by Application
14.10.1 Neurology
14.10.2 Gastroenterology
14.10.3 Cardiology
14.10.4 Oncology
14.10.5 Nephrology
14.10.6 Neuroendocrinology
14.11 Basis Point Share (BPS) Analysis by Application
14.12 Absolute $ Opportunity Assessment by Application
14.13 Market Attractiveness Analysis by Application
14.14 Middle East & Africa (MEA) Radiopharmaceuticals Market Size Forecast by Radioisotop
14.14.1 Gallium-67
14.14.2 Indium-111
14.14.3 Iodine-131
14.14.4 Fluorine-18
14.14.5 Leutetium-177
14.14.6 Iodine-125
14.14.7 Iodine-123
14.14.8 Gallium-68
14.14.9 Yttrium-90
14.14.10 Rubidium-82
14.14.11 Technetium-99
14.15 Basis Point Share (BPS) Analysis by Radioisotop
14.16 Absolute $ Opportunity Assessment by Radioisotop
14.17 Market Attractiveness Analysis by Radioisotop
Chapter 15 Competition Landscape
15.1 Radiopharmaceuticals Market: Competitive Dashboard
15.2 Global Radiopharmaceuticals Market: Market Share Analysis, 2019
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 Bayer AG
15.3.2 Advanced Accelerator Application
15.3.3 Mallinckrodt
15.3.4 Major players analyzed include GE Healthcare
15.3.5 Eckert & Ziegler
15.3.6 Jubilant Life Sciences Limited
15.3.7 Philips
15.3.8 IBA Radiopharma Solutions
15.3.9 Siemens Healthineers
15.3.10 antheus Medical Imaging Inc.
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Radiopharmaceuticals Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Radiopharmaceuticals Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Radiopharmaceuticals Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Radiopharmaceuticals Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Radiopharmaceuticals Market Size & Forecast, 2018-2028
4.5.1 Radiopharmaceuticals Market Size and Y-o-Y Growth
4.5.2 Radiopharmaceuticals Market Absolute $ Opportunity
Chapter 5 Global Radiopharmaceuticals Market Analysis and Forecast by Source
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Source
5.1.2 Basis Point Share (BPS) Analysis by Source
5.1.3 Absolute $ Opportunity Assessment by Source
5.2 Radiopharmaceuticals Market Size Forecast by Source
5.2.1 Nuclear Reactors
5.2.2 Cyclotrons
5.3 Market Attractiveness Analysis by Source
Chapter 6 Global Radiopharmaceuticals Market Analysis and Forecast by Application
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Application
6.1.2 Basis Point Share (BPS) Analysis by Application
6.1.3 Absolute $ Opportunity Assessment by Application
6.2 Radiopharmaceuticals Market Size Forecast by Application
6.2.1 Neurology
6.2.2 Gastroenterology
6.2.3 Cardiology
6.2.4 Oncology
6.2.5 Nephrology
6.2.6 Neuroendocrinology
6.3 Market Attractiveness Analysis by Application
Chapter 7 Global Radiopharmaceuticals Market Analysis and Forecast by Radioisotop
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Radioisotop
7.1.2 Basis Point Share (BPS) Analysis by Radioisotop
7.1.3 Absolute $ Opportunity Assessment by Radioisotop
7.2 Radiopharmaceuticals Market Size Forecast by Radioisotop
7.2.1 Gallium-67
7.2.2 Indium-111
7.2.3 Iodine-131
7.2.4 Fluorine-18
7.2.5 Leutetium-177
7.2.6 Iodine-125
7.2.7 Iodine-123
7.2.8 Gallium-68
7.2.9 Yttrium-90
7.2.10 Rubidium-82
7.2.11 Technetium-99
7.3 Market Attractiveness Analysis by Radioisotop
Chapter 8 Global Radiopharmaceuticals Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Radiopharmaceuticals Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Radiopharmaceuticals Analysis and Forecast
10.1 Introduction
10.2 North America Radiopharmaceuticals Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Radiopharmaceuticals Market Size Forecast by Source
10.6.1 Nuclear Reactors
10.6.2 Cyclotrons
10.7 Basis Point Share (BPS) Analysis by Source
10.8 Absolute $ Opportunity Assessment by Source
10.9 Market Attractiveness Analysis by Source
10.10 North America Radiopharmaceuticals Market Size Forecast by Application
10.10.1 Neurology
10.10.2 Gastroenterology
10.10.3 Cardiology
10.10.4 Oncology
10.10.5 Nephrology
10.10.6 Neuroendocrinology
10.11 Basis Point Share (BPS) Analysis by Application
10.12 Absolute $ Opportunity Assessment by Application
10.13 Market Attractiveness Analysis by Application
10.14 North America Radiopharmaceuticals Market Size Forecast by Radioisotop
10.14.1 Gallium-67
10.14.2 Indium-111
10.14.3 Iodine-131
10.14.4 Fluorine-18
10.14.5 Leutetium-177
10.14.6 Iodine-125
10.14.7 Iodine-123
10.14.8 Gallium-68
10.14.9 Yttrium-90
10.14.10 Rubidium-82
10.14.11 Technetium-99
10.15 Basis Point Share (BPS) Analysis by Radioisotop
10.16 Absolute $ Opportunity Assessment by Radioisotop
10.17 Market Attractiveness Analysis by Radioisotop
Chapter 11 Europe Radiopharmaceuticals Analysis and Forecast
11.1 Introduction
11.2 Europe Radiopharmaceuticals Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Radiopharmaceuticals Market Size Forecast by Source
11.6.1 Nuclear Reactors
11.6.2 Cyclotrons
11.7 Basis Point Share (BPS) Analysis by Source
11.8 Absolute $ Opportunity Assessment by Source
11.9 Market Attractiveness Analysis by Source
11.10 Europe Radiopharmaceuticals Market Size Forecast by Application
11.10.1 Neurology
11.10.2 Gastroenterology
11.10.3 Cardiology
11.10.4 Oncology
11.10.5 Nephrology
11.10.6 Neuroendocrinology
11.11 Basis Point Share (BPS) Analysis by Application
11.12 Absolute $ Opportunity Assessment by Application
11.13 Market Attractiveness Analysis by Application
11.14 Europe Radiopharmaceuticals Market Size Forecast by Radioisotop
11.14.1 Gallium-67
11.14.2 Indium-111
11.14.3 Iodine-131
11.14.4 Fluorine-18
11.14.5 Leutetium-177
11.14.6 Iodine-125
11.14.7 Iodine-123
11.14.8 Gallium-68
11.14.9 Yttrium-90
11.14.10 Rubidium-82
11.14.11 Technetium-99
11.15 Basis Point Share (BPS) Analysis by Radioisotop
11.16 Absolute $ Opportunity Assessment by Radioisotop
11.17 Market Attractiveness Analysis by Radioisotop
Chapter 12 Asia Pacific Radiopharmaceuticals Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Radiopharmaceuticals Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Radiopharmaceuticals Market Size Forecast by Source
12.6.1 Nuclear Reactors
12.6.2 Cyclotrons
12.7 Basis Point Share (BPS) Analysis by Source
12.8 Absolute $ Opportunity Assessment by Source
12.9 Market Attractiveness Analysis by Source
12.10 Asia Pacific Radiopharmaceuticals Market Size Forecast by Application
12.10.1 Neurology
12.10.2 Gastroenterology
12.10.3 Cardiology
12.10.4 Oncology
12.10.5 Nephrology
12.10.6 Neuroendocrinology
12.11 Basis Point Share (BPS) Analysis by Application
12.12 Absolute $ Opportunity Assessment by Application
12.13 Market Attractiveness Analysis by Application
12.14 Asia Pacific Radiopharmaceuticals Market Size Forecast by Radioisotop
12.14.1 Gallium-67
12.14.2 Indium-111
12.14.3 Iodine-131
12.14.4 Fluorine-18
12.14.5 Leutetium-177
12.14.6 Iodine-125
12.14.7 Iodine-123
12.14.8 Gallium-68
12.14.9 Yttrium-90
12.14.10 Rubidium-82
12.14.11 Technetium-99
12.15 Basis Point Share (BPS) Analysis by Radioisotop
12.16 Absolute $ Opportunity Assessment by Radioisotop
12.17 Market Attractiveness Analysis by Radioisotop
Chapter 13 Latin America Radiopharmaceuticals Analysis and Forecast
13.1 Introduction
13.2 Latin America Radiopharmaceuticals Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Radiopharmaceuticals Market Size Forecast by Source
13.6.1 Nuclear Reactors
13.6.2 Cyclotrons
13.7 Basis Point Share (BPS) Analysis by Source
13.8 Absolute $ Opportunity Assessment by Source
13.9 Market Attractiveness Analysis by Source
13.10 Latin America Radiopharmaceuticals Market Size Forecast by Application
13.10.1 Neurology
13.10.2 Gastroenterology
13.10.3 Cardiology
13.10.4 Oncology
13.10.5 Nephrology
13.10.6 Neuroendocrinology
13.11 Basis Point Share (BPS) Analysis by Application
13.12 Absolute $ Opportunity Assessment by Application
13.13 Market Attractiveness Analysis by Application
13.14 Latin America Radiopharmaceuticals Market Size Forecast by Radioisotop
13.14.1 Gallium-67
13.14.2 Indium-111
13.14.3 Iodine-131
13.14.4 Fluorine-18
13.14.5 Leutetium-177
13.14.6 Iodine-125
13.14.7 Iodine-123
13.14.8 Gallium-68
13.14.9 Yttrium-90
13.14.10 Rubidium-82
13.14.11 Technetium-99
13.15 Basis Point Share (BPS) Analysis by Radioisotop
13.16 Absolute $ Opportunity Assessment by Radioisotop
13.17 Market Attractiveness Analysis by Radioisotop
Chapter 14 Middle East & Africa (MEA) Radiopharmaceuticals Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Radiopharmaceuticals Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Radiopharmaceuticals Market Size Forecast by Source
14.6.1 Nuclear Reactors
14.6.2 Cyclotrons
14.7 Basis Point Share (BPS) Analysis by Source
14.8 Absolute $ Opportunity Assessment by Source
14.9 Market Attractiveness Analysis by Source
14.10 Middle East & Africa (MEA) Radiopharmaceuticals Market Size Forecast by Application
14.10.1 Neurology
14.10.2 Gastroenterology
14.10.3 Cardiology
14.10.4 Oncology
14.10.5 Nephrology
14.10.6 Neuroendocrinology
14.11 Basis Point Share (BPS) Analysis by Application
14.12 Absolute $ Opportunity Assessment by Application
14.13 Market Attractiveness Analysis by Application
14.14 Middle East & Africa (MEA) Radiopharmaceuticals Market Size Forecast by Radioisotop
14.14.1 Gallium-67
14.14.2 Indium-111
14.14.3 Iodine-131
14.14.4 Fluorine-18
14.14.5 Leutetium-177
14.14.6 Iodine-125
14.14.7 Iodine-123
14.14.8 Gallium-68
14.14.9 Yttrium-90
14.14.10 Rubidium-82
14.14.11 Technetium-99
14.15 Basis Point Share (BPS) Analysis by Radioisotop
14.16 Absolute $ Opportunity Assessment by Radioisotop
14.17 Market Attractiveness Analysis by Radioisotop
Chapter 15 Competition Landscape
15.1 Radiopharmaceuticals Market: Competitive Dashboard
15.2 Global Radiopharmaceuticals Market: Market Share Analysis, 2019
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 Bayer AG
15.3.2 Advanced Accelerator Application
15.3.3 Mallinckrodt
15.3.4 Major players analyzed include GE Healthcare
15.3.5 Eckert & Ziegler
15.3.6 Jubilant Life Sciences Limited
15.3.7 Philips
15.3.8 IBA Radiopharma Solutions
15.3.9 Siemens Healthineers
15.3.10 antheus Medical Imaging Inc.
Segments Covered in the Report
The global Radiopharmaceuticals market has been segmented based on
By Source
The global Radiopharmaceuticals market has been segmented based on
By Source
- Nuclear Reactors
- Cyclotrons
- Neurology
- Gastroenterology
- Cardiology
- Oncology
- Nephrology
- Neuroendocrinology
- Gallium-67
- Indium-111
- Iodine-131
- Fluorine-18
- Leutetium-177
- Iodine-125
- Iodine-123
- Gallium-68
- Yttrium-90
- Rubidium-82
- Technetium-99
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Bayer AG
- Advanced Accelerator Application
- Mallinckrodt
- Major players analyzed include GE Healthcare
- Eckert & Ziegler
- Jubilant Life Sciences Limited
- Philips
- IBA Radiopharma Solutions
- Siemens Healthineers
- antheus Medical Imaging Inc.
Our Clients
Related Reports
Some other reports from this category!
